Nemunaitis, J.; Stanbery, L.; Willoughby, D.; Bognar, E.; Brun, S.; Walter, A.; Monk, B.J.; Rocconi, R.P.; Choucair, K.; Coleman, R.L.
Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response. Cancers 2023, 15, 5616.
https://doi.org/10.3390/cancers15235616
AMA Style
Nemunaitis J, Stanbery L, Willoughby D, Bognar E, Brun S, Walter A, Monk BJ, Rocconi RP, Choucair K, Coleman RL.
Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response. Cancers. 2023; 15(23):5616.
https://doi.org/10.3390/cancers15235616
Chicago/Turabian Style
Nemunaitis, John, Laura Stanbery, David Willoughby, Ernest Bognar, Scott Brun, Adam Walter, Bradley J. Monk, Rodney P. Rocconi, Khalil Choucair, and Robert L. Coleman.
2023. "Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response" Cancers 15, no. 23: 5616.
https://doi.org/10.3390/cancers15235616
APA Style
Nemunaitis, J., Stanbery, L., Willoughby, D., Bognar, E., Brun, S., Walter, A., Monk, B. J., Rocconi, R. P., Choucair, K., & Coleman, R. L.
(2023). Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response. Cancers, 15(23), 5616.
https://doi.org/10.3390/cancers15235616